Pharmaceutical

#Bioinformatics #Informatics #Pharmaceutical #Phosphoproteomic

Is this start-up a game changer for drug discovery?  

Jane Theaker, Kinomica explains why she was so impressed with the preclinical datasets predicting for drug response that the company could produce, she decided to join as CEO. Kinomica is a spin out offering phosphoproteomic analyses to the pharmaceutical industry. Theaker has R&D expertise in novel diagnostic technologies. Her experience… Read More

#News #Start-up Zone

#Biotechnology #Drug development #Drug discovery #Health #Life sciences #Narrated podcasts #Pharmaceutical

2030 Life Sciences and Health in the Digital Age (Part 1)

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on… Read More

#Podcasts

#Biopharmaceuticals #Biotechnology #Mammalian transient protein #Pharmaceutical

Mammalian transient protein expression market players eye opportunities in biopharma

Global mammalian transient protein market revenues are projected to surpass US$ 540 million in 2020, according to a new study by Future Market Insights. The report also states that, innovations in automation and recombinant proteins will support market developments, however, prohibitive costs and complexity to maintain media purity remain challenges. Read More

#Market Reports #News

#Biologics / Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

Seppic boosts presence in the human vaccine adjuvant market

Seppic’s Sepivac SWETM vaccine adjuvant for human use can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as COVID-19. Together with various international partners, Seppic is participating in the global research effort to develop a vaccine solution against COVID-19. These programs are in… Read More

#Covid-19 #News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Biotechnology #Drug development #Drug discovery #Life sciences #Narrated podcasts #Pharmaceutical #Research

Evolution of User Experience for life sciences

Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to… Read More

#Podcasts

#Covid-19 #Pharmaceutical #Research & development

UK pharma sector R&D spending at 8-year high

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. Read More

#Editor's Choice #News #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

It’s never been more important to talk about vaccines, says head of pharma organisation

Richard Torbett, Chief Executive, ABPI says vaccines are one of our best hopes for eradicating COVID-19 and why the ABPI is launching a campaign to highlight this. “COVID-19 has put shone a spotlight on the pharmaceutical industry like never before. Millions of people all over the world are living under… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Gene therapy #Pharmaceutical

CEVEC signs agreement with Roche for gene therapy technology

CEVEC Pharmaceuticals has signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC will grant Roche, and Spark Therapeutics, a member of the… Read More

#News

#Biotechnology #Drug development #Drug discovery #Narrated podcasts #Pharmaceutical

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of… Read More

#Podcasts

#Pharmaceutical #Sustainability

GSK sets environmental goals of zero impact on climate by 2030

GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030. The new goals form part of GSK’s Trust priority and ESG approach, which support the company’s aim to create… Read More

#News

#Drug candidates #Live bio therapeutics #Pharmaceutical

4D pharma merger with Longevity to gain NASDAQ listing

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. Read More

#News

#Biotechnology #Drug development #Drug discovery #Life sciences #Narrated podcasts #Pharmaceutical

Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency

This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of… Read More

#Podcasts